Reducing the expression of proinflammatory genes by activating the PPARγ is considered to contribute to the NSAIDs protective features against AD [63-66], and therefore Pioglitazone has gained a great deal of attention as a potential treatment for AD. Here, PPARG is linked to Alzheimer disease.